The Company at present is ready with the commercial launch of the following products developed by it - Atorvastatin, Fexofenadine, Rosuvastatin, Temozolamide and Ivabradine. The Company expects to capture a market size in the range of 10% to 20% of the generic market of these drugs in the coming years up on commercial launch.

The fund raised will enable the company to have capacities to manufacture these products at commercial pace.